Company intelligence / Profile preview
Diabetes Free
New York, New York, United Statesdiabetesfree.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Diabetes Free is a clinical-stage platform biotechnology company focused on antigen-specific immune tolerance across autoimmunity, transplantation, and oncology. The company's proprietary platform, anchored by rational antibody engineering, aims to achieve 'Immune Reset' through synchronous deep B-cell depletion and T-cell modulation. Its pipeline includes DFI 105, a first-in-class subcutaneous allosteric anti-CD40 monoclonal antibody in development for transplantation and multiple sclerosis, and DFI 205, a bivalent bispecific antibody targeting CD20 and CD40 for autoimmune diseases. Additionally, the company is evaluating ToleraCell, an apoptotic donor leukocyte cell therapy, in a Phase 1/2 trial to induce tolerance in islet allotransplantation for Type 2 diabetes.
- Therapeutic areas
- ImmunologyEndocrinologyNeurologyOncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyTrispecific antibodyCell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of Minnesota
Beyond the preview
Go deeper on Diabetes Free.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diabetes Free.